Long-term Study to Evaluate Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants

Jaw, Edentulous Clinical Trial

Official title:

Long-term, Prospective, Cohort Study to Evaluate Safety and Efficacy of Two Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants for Removable Prosthesis in Patients With Edentulous Mandibles

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01878331
• Other study ID #: CR 01/13
• Status: Completed
• Start date: June 2013
• Est. completion date: September 2018

Study information

• Verified date: January 2020
• Source: Institut Straumann AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patients with an edentulous mandible restored with implants who have participated in the core study CR 04/07 will be recruited for this extension study. No further interventions will be made for this extension study other than a clinical follow-up examination and questionnaires. Patients will not receive an investigational treatment in this study. Patients will be followed at 5 to 10 years from the date of the original implant loading

Description:

The primary study objective is to compare implant survival with the Titanium Zirconium (Roxolid™) implant compared the Titanium grade IV (SLActive®) implant between baseline (surgery) and 10 years.

The following outcome parameters will be evaluated at 5 and 10 years post surgery for the two different implant types Straumann® Bone Level SLActive, diameter 3.3 mm, Titanium-Zirconium (Roxolid®) vs. Straumann® Bone Level SLActive implant, diameter 3.3 mm, Titanium Grade IV:

• Implant survival

• Implant success according to Buser et al. (1990)

• Crestal bone level change measured by Orthopantomogram (OPT)

• Soft tissue health

• Clinical measurements

• Prosthetic parts assessments: Success and maintenance

• Oral Health Related Quality of Life (OHRQoL)

• Product Safety (Adverse events and device deficiencies)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have voluntarily signed the informed consent form

• Patients must be committed to participate in the study until the ten year follow-up examinations

• Subjects must have received treatment in the CR 04/07 core study

• Subjects must have completed 3 year visit of core study

Exclusion Criteria:

• Physical handicaps that would interfere with the ability to perform adequate oral hygiene or attend follow up visits

• Use of any investigational drug or device during the study

• Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, unreliability

Related Conditions & MeSH terms

• Jaw, Edentulous
• Mouth, Edentulous

Locations

Country	Name	City	State
Switzerland	Frauke Müller	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
Institut Straumann AG

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implant Survival	This is a long term follow up extension study including evaluations at 5 and 10 years after the implant procedure from the core study. Implant survival will be assessed based on surviving implants for all patients at 10 years.	10 years following implant procedure date
Secondary	Crestal bone level change	The change in crestal bone level will be measured on standard x-rays taken at 5 and 10 years as per standard of care. An independent reviewer will evaluate all x-rays for the analysis.	5 and 10 years